A股異動 | 萬泰生物(603392.SH)漲停 前三季度純利同比增長273.23%
格隆匯10月28日丨萬泰生物(603392.SH)漲停,封單不足一萬手,報191.4元,暫成交4億元,最新總市值829億元。萬泰生物昨日盤後公佈,公司前三季度實現營業收入15.99億元,同比增長92.61%;歸屬於上市公司股東的淨利潤4.67億元,同比增長273.23%;基本每股收益1.13元。公司業績增長主要是新增宮頸癌二價疫苗疫苗收入、新增新冠試劑銷售收入、新增技術合作收入三項所帶來的淨利潤增長所致。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.